Free Trial

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific logo
$95.41 -1.87 (-1.92%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$95.53 +0.12 (+0.12%)
As of 10/10/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
2
Buy
25

Based on 27 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Buy." Out of the 27 analysts, 2 have given a hold rating, 23 have given a buy rating, and 2 have given a strong buy rating for BSX.

Consensus Price Target

$120.71
26.51% Upside
According to the 27 analysts' twelve-month price targets for Boston Scientific, the average price target is $120.71. The highest price target for BSX is $136.00, while the lowest price target for BSX is $100.00. The average price target represents a forecasted upside of 26.51% from the current price of $95.41.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Analyst Ratings Over Time

TypeCurrent Forecast
10/12/24 to 10/12/25
1 Month Ago
9/12/24 to 9/12/25
3 Months Ago
7/14/24 to 7/14/25
1 Year Ago
10/13/23 to 10/12/24
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
23 Buy rating(s)
22 Buy rating(s)
21 Buy rating(s)
17 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$120.71$118.04$116.09$87.60
Forecasted Upside26.51% Upside14.93% Upside11.21% Upside0.57% Upside
Consensus RatingBuyBuyBuyModerate Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Boston Scientific Stock vs. The Competition

TypeBoston ScientificMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.33
2.52
Consensus RatingBuyHoldModerate Buy
Predicted Upside26.51% Upside1,022.61% Upside177.78% Upside
News Sentiment Rating
Positive News

See Recent BSX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B-)
10/7/2025Evercore ISI
3 of 5 stars
Vijay Kumar
Vijay Kumar
Not Rated
Lower TargetOutperform$115.00 ➝ $110.00+13.72%
10/3/2025Erste Group Bank
3 of 5 stars
 DowngradeBuyHold
10/2/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$133.00 ➝ $136.00+42.00%
10/1/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$131.00 ➝ $132.00+35.32%
10/1/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$125.00 ➝ $129.00+37.12%
10/1/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$127.00 ➝ $128.00+31.21%
10/1/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$123.00 ➝ $128.00+31.21%
10/1/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$127.00 ➝ $132.00+35.32%
10/1/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$121.00+24.04%
9/29/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$125.00+28.48%
9/8/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$118.00 ➝ $125.00+16.67%
7/24/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetStrong-Buy$121.00 ➝ $124.00+17.45%
7/24/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$130.00 ➝ $135.00+27.80%
7/24/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$118.00 ➝ $124.00+17.74%
7/21/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold
6/16/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$119.00 ➝ $125.00+19.59%
5/16/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$120.00 ➝ $125.00+18.58%
2/18/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$130.00+24.98%
2/6/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$100.00 ➝ $115.00+9.25%
2/3/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$95.00 ➝ $115.00+11.65%
1/10/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$108.00+12.64%
12/16/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$100.00 ➝ $110.00+21.21%
12/12/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$100.00 ➝ $110.00+21.11%
10/24/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$92.00 ➝ $100.00+16.41%
10/24/2024Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$100.00 ➝ $110.00+25.79%
10/22/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$90.00 ➝ $100.00+13.39%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$90.00+20.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:24 PM ET.


Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 11, 2025. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Recent analyst upgrades have increased the target price for Boston Scientific Co. to as high as $135.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $96.73, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $109.50.
  • Boston Scientific Co. has a solid market capitalization of approximately $143.33 billion, reflecting its strong position in the medical device industry.
  • Insider trading activity shows that executives are actively managing their positions, which can indicate confidence in the company's future performance.
  • The company has received multiple "buy" ratings from analysts, suggesting a consensus that the stock is a favorable investment.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Insider selling has been significant, with over 174,000 shares sold recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced a decrease in ownership percentages among insiders, which could signal a lack of confidence in the company's future prospects.
  • Despite positive analyst ratings, the stock has shown volatility, with a recent decline of about 0.9%, indicating potential instability in the market.
  • The company's high price-to-earnings (PE) ratio of 57.58 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Boston Scientific Co. has a relatively low insider ownership of only 0.50%, which may indicate a lack of alignment between management and shareholder interests.

BSX Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $120.71, with a high forecast of $136.00 and a low forecast of $100.00.

27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 23 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 26.51% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like Boston Scientific more than other "medical" companies. The consensus rating for Boston Scientific is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how BSX compares to other companies.


This page (NYSE:BSX) was last updated on 10/12/2025 by MarketBeat.com Staff
From Our Partners